ONS member Seth Eisenberg, RN, ASN, OCN®, BMTCN®, professional practice coordinator of infusion services at Seattle Cancer Care Alliance in Washington and member of the Puget Sound ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss how to safely administer bevacizumab. This episode is part of an ongoing series about outpatient oncology drug infusion. The others are linked in the episode notes.

Music Credit: "Fireflies and Stardust" by Kevin MacLeod

Licensed under Creative Commons by Attribution 3.0

Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by June 25, 2023. Seth Eisenberg disclosed receiving a speaker honorarium from Genentech Inc. The financial relationship has been mitigated. No other planners or faculty members have anything to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center’s Commission on Accreditation.

Episode Notes

Check out these resources from today’s episode:

• The NCPD activity for this episode has expired, but you can still earn NCPD through many other Oncology Nursing Podcast episodes. Find a full list of opportunities.
• Previous Oncology Nursing Podcast episodes on outpatient oncology drug infusion
• ONS Voice article: FDA Approves Bevacizumab in Combination With Chemotherapy for Ovarian Cancer
• ONS Voice article: FDA Approves First Biosimilar for Cancer Treatment
• ONS Voice article: FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
• ONS Voice article: The Names of Targeted Therapies Give Clues to How They Work
• ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice
• ONS Communities thread on port placement
• ONS Communities thread on vital signs
• Manufacturers’ healthcare provider pages for bevacizumab and the two biosimilars currently approved at the time of this episode (bevacizumab-awwb and bevacizumab-bvzr)
• National Institute for Occupational Safety and Health list of hazardous drugs

To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.